New drug cocktail aims to slow tough prostate cancer

NCT ID NCT03517969

Ongoing Disease control Sponsor: National Cancer Institute (NCI) Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 31, 2026 · Updated 1 time

Summary

This study tests whether adding an experimental drug (M6620) to standard chemotherapy can better shrink tumors or slow the disease in men with advanced prostate cancer that no longer responds to hormone therapy. About 73 participants will receive either M6620 plus carboplatin or docetaxel plus carboplatin. The goal is to see if the new combination improves response rates and delays cancer growth.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CASTRATION-RESISTANT PROSTATE CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

castration-resistant prostate carcinoma metastatic prostate carcinoma prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CASTRATION-RESISTANT PROSTATE CARCINOMA METASTATIC PROSTATE CARCINOMA STAGE IV PROSTATE CANCER AJCC V8

Contacts and locations

Locations

Beth Israel Deaconess Medical Center

Boston, Massachusetts, 02215, United States
City of Hope Comprehensive Cancer Center

Duarte, California, 91010, United States
Dana-Farber Cancer Institute

Boston, Massachusetts, 02215, United States
Ohio State University Comprehensive Cancer Center

Columbus, Ohio, 43210, United States
Rutgers Cancer Institute of New Jersey

New Brunswick, New Jersey, 08903, United States
Smilow Cancer Center/Yale-New Haven Hospital

New Haven, Connecticut, 06510, United States
Smilow Cancer Hospital Care Center - Guilford

Guilford, Connecticut, 06437, United States
Smilow Cancer Hospital Care Center - Waterford

Waterford, Connecticut, 06385, United States
Smilow Cancer Hospital Care Center at Saint Francis

Hartford, Connecticut, 06105, United States
Smilow Cancer Hospital Care Center-Fairfield

Fairfield, Connecticut, 06824, United States
Smilow Cancer Hospital Care Center-Trumbull

Trumbull, Connecticut, 06611, United States
Smilow Cancer Hospital-Derby Care Center

Derby, Connecticut, 06418, United States
Smilow Cancer Hospital-Orange Care Center

Orange, Connecticut, 06477, United States
Smilow Cancer Hospital-Torrington Care Center

Torrington, Connecticut, 06790, United States
Smilow Cancer Hospital-Waterbury Care Center

Waterbury, Connecticut, 06708, United States
UC San Diego Moores Cancer Center

La Jolla, California, 92093, United States
UCHealth University of Colorado Hospital

Aurora, Colorado, 80045, United States
UPMC Hillman Cancer Center

Pittsburgh, Pennsylvania, 15232, United States
University of California Davis Comprehensive Cancer Center

Sacramento, California, 95817, United States
VCU Massey Comprehensive Cancer Center

Richmond, Virginia, 23298, United States
Wayne State University/Karmanos Cancer Institute

Detroit, Michigan, 48201, United States
Yale University

New Haven, Connecticut, 06520, United States
Yale-New Haven Hospital North Haven Medical Center

North Haven, Connecticut, 06473, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.